At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 743 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)
In Brief
A Phase 3 clinical trial evaluating Nivolumab and Sorafenib for Hepatocellular Carcinoma. Completed, enrolled 743 participants across 138 sites in 22 countries.
Detailed Summary
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesAustralia, Austria, Belgium, Canada, China, Czechia, France, Germany, Hong Kong, Israel, Italy, Japan, Poland, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
CollaboratorsOno Pharmaceutical Co., Ltd.
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartDec 2015
Primary CompletionMay 2019
Study CompletionFeb 2024
TodayJul 2026
First PostedOct 15, 2015
Enrollment StartDec 7, 2015
Primary CompletionMay 30, 2019
Study CompletionFeb 7, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.7 years ago
Interventions
Nivolumabdrug
Specified Dose on Specified Days
Sorafenibdrug
Specified Dose on Specified Days